论文部分内容阅读
目的探讨希罗达联合经肝动脉栓塞化疗(TACE)治疗晚期原发性肝癌的有效性。方法30例不能手术切除的晚期肝癌患者(TNM分期Ⅱ期)随机分成两组:(1)单纯TACE组16例;(2)希罗达联合TACE组(X+TACE)14例,在TACE治疗后第2天,口服给药14d。全部患者随访4~24个月。比较两组患者的中位生存时间、6个月和1年生存率、死亡患者平均生存时间。结果X+TACE治疗组患者的中位生存时间为14.5个月,6个月和1年生存率分别为78.6％和64.3％,显著高于TACE组(31.2％和6.2％)(P<0.01)。结论希罗达联合TACE治疗晚期原发性肝癌患者的疗效优于单纯TACE。
Objective To investigate the efficacy of Xeloda combined with transcatheter arterial chemoembolization (TACE) in the treatment of advanced primary liver cancer. Methods Thirty patients with unresectable advanced hepatocellular carcinoma (stage II TNM) were randomly divided into two groups: (1) 16 patients in the TACE group alone; (2) Xeloda plus TACE group (X+TACE) in 14 patients treated with TACE. On the second day after oral administration, 14 days. All patients were followed up for 4 to 24 months. The median survival time, 6-month and 1-year survival rates, and the average survival time of death patients were compared between the two groups. Results The median survival time of patients in the X+TACE group was 14.5 months. The 6-month and 1-year survival rates were 78.6% and 64.3%, respectively, which were significantly higher than those in the TACE group (31.2% and 6.2%) (P<0.01). . Conclusion Xeloda combined with TACE is superior to TACE in the treatment of patients with advanced primary liver cancer.